A recent study shows that women who received a combination breast cancer chemotherapy regimen referred to as CMF between 1976 and 1995 performed worse on cognitive tests compared with women who never had cancer. The subtle differences in performance were statistically significant and occurred primarily in word learning and memory and information processing speed.
The findings, published February 27 in the Journal of Clinical Oncology, indicate that cognitive problems may be observed 20 years following chemotherapy treatment.
New research recommends nurses play a key role in alleviating the concerns of newly diagnosed cancer patients. This interaction will lead to a better quality of life for anxious patients, according to a paper published in the current edition of the Clinical Journal of Oncology Nursing.
Recent findings show that female cancer survivors receiving screening mammography display “worse health behaviors” than women receiving mammography screening who have never had cancer.
The study, conducted by researchers at Moffitt Cancer Center in Tampa, FL, and the Mayo Clinic in Rochester, MN, was published in a recent issue of the American Journal of Clinical Oncology.
The first molecular test to help determine the need for repeat prostate biopsies in men who have had a previous negative biopsy has been approved by the FDA.
Anticipating future events may contribute to stress-related increased risk for the diseases of aging, including cancer, according to a study to be published in the May issue of the journal Brain, Behavior and Immunity.
Many women endure hot flashes and night sweats following breast cancer treatment. British researchers are now saying that cognitive behavioral therapy (CBT) is an effective treatment for women experiencing these main symptoms of menopause.
A warning has been issued by the FDA regarding a counterfeit version of Avastin 400 mg/16 mL, which may have been purchased and utilized by medical practices in the United States. Chemical analyses of the imitation vials have confirmed the product lacks the active ingredient of Avastin, bevacizumab, which may have resulted in patients not receiving needed therapy.
Packages or vials may be counterfeit if:
A newly patented computerized system effectively chooses the right patient for the right clinical trial. The program quickly matches a registered patient’s molecular profile to a disease-targeting drug’s molecular design. According to the Moffit Cancer Center, the system will accelerate clinical trials and help reduce the time required for critical new drugs to reach the market.
For the first time, the effect of exemestane on women’s bone health has been studied, and researchers found that, on 3 major outcome measures, age-related bone loss in postmenopausal women taking exemestane for 2 years worsened.
“The study is important because of the potential for wide-spread use of this medication by women at increased risk of developing breast cancer,” said Dr Lianne Tile, Medical Director of the Osteoporosis Clinic and Staff General Internist at University Health Network, and one of the authors of the study.
Cachexia affects many patients with advanced cancer. It causes excessive weight loss, severe fatigue, and diminishes quality of life. Now, new research has found that patients with severe cancer-related fatigue also have less muscle mass and strength compared with patients who are less impaired.
“Ours is the first study to identify the relationship between chronic fatigue and muscle mass and strength in this special patient population,” says first author Robert Kilgour, professor and chair of Concordia University’s Department of Exercise Science.
To sign up for our newsletter or print publications, please enter your contact information below.
